9am-5pm EST | 3pm-11pm CET

8:00 am Morning Networking Coffee


Grab a quick cup of tea or coffee from the comfort of your own home office and start chatting with your peers in a virtual coffee room.

8:25 am Chair’s Opening Remarks

An Overview of the Current Treatment Landscape:
What Do We Know? & What is on the Horizon?

9:00 am After 80 Years of Targeting the Androgen Receptor in Prostate Cancer

  • Vivek Arora Director, Translational Medicine,Early Clinical Development, Hematology/ Oncology & Cell Therapy, Bristol-Myers Squibb (BMS)


• Overview of biology and historical advancements in prostate cancer drug development
• Hear a summary of the major therapeutic strategies currently under development
• Discuss barriers to progress and strategies to address these

9:30 am Panel Discussion: Overview of Emerging Therapeutic Targets

  • Ellen Filvaroff Executive Director in Translational Development, Bristol-Myers Squibb (BMS)
  • Sumit Subudhi Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center
  • Ramesh Narayanan Professor of the Department of Medicine & Director of Center for Cancer Drug Discovery, University of Tennessee Health Science Center
  • Frank Lin Chief, Targeted Radionuclide Therapy Section, Lasker Clinical Research Scholar Molecular Imaging Program, NCI/NIH
  • Eric Campeau Senior Director of Translational Medicine, Zenith Epigenetics


• Examine the current treatment options and emerging targeted therapies: What approaches do we currently have? What are their limitations?
• Discuss what is the role of the tumor micro-environment in mCRPC
• Evaluate how the combination of several targeted therapies can be of benefit to patients with prostate cancer, when these therapies show limited efficacy as single agents
• Hear what research is urgently required to identify actionable therapeutic targets in mCRPC: How can the industry design novel therapeutic strategies for the treatment of mCRPC?

Are We at Limits with Androgen Receptors?
Importance of Androgen Signalling & Advances to Effectively Target the Signalling Pathway

10:15 am Optimize Next-generation Small Molecule Inhibitors, Degraders of Androgen Receptor (AR) & AR-splice Variant

  • Ramesh Narayanan Professor of the Department of Medicine & Director of Center for Cancer Drug Discovery, University of Tennessee Health Science Center


• Examine novel small molecule degraders and antagonists that bind to the N-terminus-domain of the androgen receptor, and inhibit prostate cancer in preclinical models
• Understand how molecules possess excellent pharmacokinetic and drug-like properties
• Learn about early toxicology studies suggesting good safety profile
• Discuss novel mechanisms of action

10:45 am Morning Break & Virtual Speed Networking


Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange virtual business cards. Form lasting connections through this exclusive virtual speed networking!

11:15 am Spotlight on VERU-111; An Oral Cytoskeletal Disruptor for the Treatment of Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) who Failed an Androgen Receptor Targeting Agent


• Explore an oral agent with a novel mechanism of action with good efficacy and safety in Phase 1b and Phase 2 clinical studies
• Examine how it is well tolerated at daily continuous oral dosing
• Take a look at the Phase 3 VERACITY clinical trial that is in progress in men with metastatic castration resistant prostate cancer who have failed at least one androgen receptor targeting agent

11:45 am Blocking the N-terminal Domain of the Adrogen Receptor (AR) in Prostate Cancer: A New Frontier

  • Alessandra Cesano Chief Medical Officer, ESSA Pharmaceuticals
  • Ronan LeMoigne Executive Director, Preclinical Development & Translational Medicine, ESSA Pharmaceuticals


• Understand the effects of interfering with androgen synthesis centrally peripherally or with the binding of androgens to the ligand-binding domain (LBD)
• Review how a functional N-terminal domain (NTD) is essential for activation of the AR
• Examine EPI-7386, the newest of the “anitens”, a new class of compounds designed to inhibit AR activity by binding to the N-terminal domain (NTD) of the AR
• Discuss preclinical and clinical pharmacology of compound EPI-7386: A highly selective, oral, small currently being studied in a Phase 1 clinical trial in men with whose tumors have progressed on current standard-of care therapies

12:15 pm Examine MAPK4 as a Novel Therapy Target for Lethal Prostate Cancer

  • Feng Yang Assistant Professor Molecular & Cellular Biology, Baylor College of Medicine Houston


• Review MAPK4 as an atypical MAPK that was not well studied and its biology in human cancers was largely unknown
• Explore a pioneering study on MAPK4 promoting tumor progression via noncanonical activation of AKT/mTOR signaling
• Discuss the discovery of MAPK4 promoting prostate cancer growth and therapy-resistance by concerted activation of GATA2/AR and AKT pathway
• Learn what critical reagents are needed to translate these new discoveries into clinical usage

12:45 pm Lunch Break & Virtual Networking


• Live Demo in Virtual Exhibition Hall
• 1-1 Meetings

Optimizing Advances in Immunotherapy:
Why do Current Immunotherapy Approaches Not Work as Well? Will Immunotherapy Ever Work for Prostate Cancer?

1:45 pm Showcasing Autologous and Allogeneic Tscm CAR-T Programs for Prostate Cancer

  • Julia Coronella Executive Director, Immuno-Oncology, Poseida Therapeutics


• Examine how Poseida’s piggyBac® transposon system DNA Delivery System creates Tscm-enriched CAR-T, which may have advantages for the treatment of solid tumors
• Explore how P-PSMA-101 autologous PSMA-targeting CAR-T demonstrates robust preclinical activity and promising early signals in phase I
• Analyze how P-PSMA-ALLO1 fully allogeneic PSMA-targeting CAR-T produced with utilizing Cas-CLOVER gene editing retains favourable Tscm biology and potency, while also providing the advantage of off-the-shelf production from healthy donor cells

2:15 pm Optimize the Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer

  • Ravi Madan Senior Clinician & Clinical Director, Genitourinary Malignancies Branch, NIC/NIH


• Assess the significant biological differences between advanced prostate cancer and biochemically recurrent (non-metastatic castration sensitive) disease
• Examine several studies suggesting that immunotherapy impacts PSA in this biochemically recurrent prostate cancer
• Discuss additional studies investigating immunotherapy combinations in this setting
• Analyze the emergence of PET imaging and how it impacts how biochemically recurrent prostate cancer is evaluated and treated

2:45 pm Radioligand Therapy as a Potential Treatment for Advanced Prostate Cancer

  • Andrew Cavey Global Program Head, Prostate Cancer, Novartis/Advanced Accelerator Applications


• Explore 177Lu-PSMA-617, an investigational first-in-class therapy for mCRPC
• Discuss advances in the clinical development of PSMA-targeted radioligand therapy (RLT)
• Examine the next scientific and clinical frontiers for PSMA-RLT

3:15 pm Virtual Speed Networking


Recreating the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new business

3:45 pm Spotlight on HPN424; a Novel, Half-life extended, PSMA/ CD3 specific TriTAC for the Treatment of Metastatic Prostate Cancer

  • Yifah Yaron Executive Medical Director, Harpoon Therapeutics


• Understand HPN424; a small (~50kD), single-chain, globular protein of three antibody fragment-based domains that target PSMA, CD3 and albumin
• Examine how “TriTAC” (Tri-specific T Cell Activating Construct) design has been optimized to recruit T cells at low target density, penetrate solid tumors more efficiently, and has extended serum half-life
• Take a look at a currently ongoing phase 1 dose escalation trial to assess safety and provide preliminary efficacy data for once-weekly administered HPN424 in patients with mCRPC
• Evaluate how HPN424 represents a novel, half-life extended, PSMAtargeting T cell engager that can be safely administered in a heavily pre-treated prostate cancer population

4:15 pm Advance Bispecific T-Cell Engager Immune Therapies for the Treatment of Prostate Cancer


• Examine AMG 212 as first evidence for BiTE molecule activity in prostate cancer
• Discuss interim data of next-generation BiTE immune therapy AMG 160 in mCRPC
• Explore PSMA, STEAP1 and DLL3 targets and T cell engagers in prostate cancer

4:45 pm Develop Opportunities & Challenges for T-cell Directed Therapies in Prostate Cancer

  • Ben Tran Medical Oncologist & Associate Professor, Peter MacCallum Cancer Centre


• Understand how prostate cancer is thought to be an immune dessert
• Examine how developing immunotherapy in prostate cancer has been consistently difficult
• Assess how T-cell directed therapies appear to be a game-changer

5:15 pm Chair Closing Remarks